JS207, Junshi Biosciences’ independently developed recombinant humanized anti-PD-1/VEGF bispecific antibody, has demonstrated promising anti-tumor activity and a manageable safety profile in both ...
Complete response rate was 37%, and post-hoc end point of objective response rate was 89%. HealthDay News — Patients with advanced desmoplastic melanoma have high response to single-agent ...
In the article that accompanies this editorial, Wong et al 18 demonstrate significant clinical activity with tolerable toxicities of the second-generation oncolytic virus vusolimogene oderparepvec ...
RFA and anti-PD-1 combination therapy suppresses abscopal HCC tumors and prevents recurrence in mice
Hepatocellular carcinoma (HCC), the most prevalent form of primary liver cancer, remains a leading cause of cancer-related mortality worldwide. Although radiofrequency ablation (RFA) is the first-line ...
TAR-200 for Bacillus Calmette-Guérin–Unresponsive High-Risk Non–Muscle-Invasive Bladder Cancer: Results From the Phase IIb SunRISe-1 Study Of 140 patients enrolled, 48.6% had stage IVM1b/c/d disease, ...
We would like to comment on Schuler et al., on their well-designed randomized phase II NEOpredict-Lung study (NCT04205552) which was published in Nature Medicine. The main objective of this study was ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results